GlassScriptPhysician profile
Amanda R Lipscomb
NPI 1316207186
$6,587.46
in general payments reported to CMS, 2019-2025
27 companies · $2,018 in 2025
The $2,018 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $505 · 2022: $938 · 2023: $1,119 · 2024: $2,008 · 2025: $2,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,145.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,993.26 | 2021-2025 | |
| Janssen Biotech, INC. | $1,016.16 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $734.27 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $494.19 | 2021-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $440.53 | 2021-2025 | |
| Madrigal Pharmaceuticals | $355.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $235.28 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $187.39 | 2023-2025 | Ibsrela |
| Pfizer INC. | $173.10 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $160.27 | 2021-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $116.45 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $114.79 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $104.25 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $60.49 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $57.56 | 2025 | Iqirvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $48.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.37 | 2022-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $38.59 | 2025 | Terlivaz |
| Fresenius Kabi USA, LLC | $37.69 | 2023-2024 | Idacio |
| Genzyme Corporation | $32.81 | 2022 | |
| Lilly USA, LLC | $31.81 | 2024 | Omvoh |
| Mirum Pharmaceuticals, INC. | $24.51 | 2025 | Livmarli |
| Nestle Healthcare Nutrition INC. | $21.98 | 2023 | |
| Vivus LLC | $21.72 | 2025 | Pancreaze |
| Boston Scientific Corporation | $17.83 | 2025 | Axonics |
| Ferring Pharmaceuticals INC. | $14.68 | 2022 | |
| Alfasigma USA, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lipscomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.